About the Company
we are leading the gene therapy revolution. our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing – providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. we have a lot of energy, and it’s not just the abundance of coffee that keeps us going. find out what sparks our excitement and inspires us every day.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BLUE News
Bluebird secures up to $175M in debt financing deal
Bluebird bio Inc. says it's taken steps to strengthen its balance sheet as the company executes the commercial launches for ...
Bluebird secures up to $175M financing amid gene therapy launches
Bluebird bio (NASDAQ:BLUE) said it has secured up to $175M in debt financing through an agreement with Hercules Capital (HTGC ...
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
March 18, 2024--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it has entered into a $175 million five-year, term loan facility with Hercules ...
Bluebird, short on cash, takes on $175M in debt financing
The funding could extend the cash-strapped gene therapy maker’s financial runway to 2026, but only if the company successfully hits certain milestones.
Bluebird Bio Secures Debt Financing - Quick Facts
(RTTNews) - bluebird bio, Inc. (BLUE) has entered into a $175 million five-year, term loan facility with Hercules Capital, Inc. (HTGC). The term loan facility provides for up to $175 million of term ...
Forecasting The Future: 6 Analyst Projections For bluebird bio
Insights from analysts' 12-month price targets are revealed, presenting an average target of $6.17, a high estimate of $12.00 ...
bluebird bio, Inc. (BLUE)
SOMERVILLE, Mass., March 11, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio") today announced it has signed its first Medicaid outcomes-based agreement for LYFGENIA™ (lovotibeglogene ...
Shareholder Rights Advocates at Levi & Korsinsky Investigate bluebird bio, Inc. (BLUE) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / March 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of bluebird bio, Inc. ("bluebird bio") (NASDAQ:BLUE) concerning possible ...
bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio”) today announced it has signed its first Medicaid outcomes-based agreement for LYFGENIA™ (lovotibeglogene autotemcel, also known ...
bluebird bio Inc BLE
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
bluebird bio Inc BLUE
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...